SEC Filing: AMAG Pharmaceuticals To Eliminate 45 Positions
On June 25, 2012, the Company announced plans to reduce its workforce by approximately 45 positions, the majority of which are expected to be associated with the Company’s manufacturing and development infrastructure. The Company expects to incur approximately $1.0 million in severance related charges associated with the restructuring, including approximately $0.5 million associated with employees located at the Company’s Cambridge, Massachusetts manufacturing facility, all of which are expected to be recognized during 2012. In addition, the Company announced plans to divest its Cambridge, Massachusetts manufacturing facility. At this time, the Company cannot provide an estimate of the total amount or range of amounts expected to be incurred in connection with its plan to divest its Cambridge, Massachusetts manufacturing facility or an estimate of the amount or range of amounts of the charges that will result in future cash expenditures with respect to such expected divestiture. The Company will file an amended report on Form 8-K under this Item 2.05 within four business days after it makes a determination of such estimates or ranges of estimates with respect to the expected sale of such property.
AMAG Pharmaceuticals Inc.
Citybizlist Partner News
- Davis, Malm & D'Agostine - Davis Malm Shareholder Robert J. Galvin Quoted in Noted Condominium Resource Hoaleader.com
- Pierce Atwood - Bruce Miller to Present at "Not Just Another SBA Seminar"
- Davis, Malm & D'Agostine - Tamsin R. Kaplan Presents to the Woman to Woman Group at New Directions, Inc.
- Pierce Atwood - Cliff Ruprecht & Gavin McCarthy Present at MSBA Litigation Institute